Advertisement

Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma

  • Whitney S. Graybill
    Affiliations
    Medical University of South Carolina, Hollings Cancer Center, 86 Jonathan Lucas Street, Charleston, SC 29425, United States
    Search for articles by this author
  • Bhavana Pothuri
    Affiliations
    Department of Obstetrics and Gynecology, NYU Langone Medical Center, 240 East 38th Street, 19th Floor, New York, NY 10016, United States
    Search for articles by this author
  • Dana M. Chase
    Affiliations
    Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, 2222 E. Highland Avenue, Suite 400, Phoenix, AZ 85016, United States
    Search for articles by this author
  • Bradley J. Monk
    Correspondence
    Corresponding author.
    Affiliations
    Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, 2222 E. Highland Avenue, Suite 400, Phoenix, AZ 85016, United States
    Search for articles by this author

      Highlights

      • The optimal clinical use of PARP inhibitors—as treatment or maintenance—is unclear.
      • Progression-free survival alone may be insufficient to support use as maintenance.
      • Clinicians and patients must consider various factors in each setting.
      • Potential clinical benefit must be balanced with symptoms from disease or treatment.
      • Patient perceptions, such as quality of life, should be considered in both settings.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McMeekin D.S.
        • Tillmanns T.
        • Chaudry T.
        • Gold M.
        • Johnson G.
        • Walker J.
        • et al.
        Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
        Gynecol. Oncol. 2004; 95: 157-164
        • Mei L.
        • Chen H.
        • Wei D.M.
        • Fang F.
        • Liu G.J.
        • Xie H.Y.
        • et al.
        Maintenance chemotherapy for ovarian cancer.
        Cochrane Database Syst. Rev. 2013; CD007414
        • Bast R.C.
        • Thigpen J.T.
        • Arbuck S.G.
        • Basen-Engquist K.
        • Burke L.B.
        • Freedman R.
        • et al.
        Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR public workshop.
        Gynecol. Oncol. 2007; 107: 173-176
        • Stuart G.C.
        • Kitchener H.
        • Bacon M.
        • duBois A.
        • Friedlander M.
        • Ledermann J.
        • et al.
        Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
        Int. J. Gynecol. Cancer. 2011; 21: 750-755
        • Herzog T.J.
        • Armstrong D.K.
        • Brady M.F.
        • Coleman R.L.
        • Einstein M.H.
        • Monk B.J.
        • et al.
        Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
        Gynecol. Oncol. 2014; 132: 8-17
        • Herzog T.J.
        • Alvarez R.D.
        • Secord A.
        • Goff B.A.
        • Mannel R.S.
        • Monk B.J.
        • et al.
        SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.
        Gynecol. Oncol. 2014; 135: 3-7
        • Moore K.N.
        • Monk B.J.
        Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer.
        Oncologist. 2016; 21: 954-963
        • Minion L.E.
        • Coleman R.L.
        • Alvarez R.D.
        • Herzog T.J.
        Endpoints in clinical trials: what do patients consider important? A survey of the Ovarian Cancer National Alliance.
        Gynecol. Oncol. 2016; 140: 193-198
        • Ledermann J.
        • Harter P.
        • Gourley C.
        • Friedlander M.
        • Vergote I.
        • Rustin G.
        • et al.
        Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
        N. Engl. J. Med. 2012; 366: 1382-1392
        • Mirza M.R.
        • Monk B.J.
        • Herrstedt J.
        • Oza A.M.
        • Mahner S.
        • Redondo A.
        • et al.
        Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
        N. Engl. J. Med. 2016; 375: 2154-2164
        • Foote J.
        • Liang M.
        • Secord A.A.
        • Cohn D.E.
        • Havrilesky L.J.
        Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer.
        J. Clin. Oncol. 2016; 34: 6630